Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study.

被引：1
|
作者：
Dreyling, Martin H.
Leppa, Sirpa
Comeau, Terrance
Kosinova, Marina
Lenz, Georg
Nagler, Arnon
Heo, Dae Seog
Oh, Sung Yong
Huang, Liping
Wirtz, Oliver
Miriyala, Ashok
Garcia-Vargas, Jose E.
Childs, Barrett H.
Zinzani, Pier Luigi
机构：
[1] Klin Univ Munchen LMU, Medizin Klin & Poliklin 3, Munich, Germany
[2] Helsinki Univ Cent Hosp Canc Ctr, Helsinki, Finland
[3] St Johns Hosp, St John, NB, Canada
[4] Kemerovo Reg Reg Clin Hosp, Kemerovo, Russia
[5] Munster Univ Clin, Translat Oncol Med Clin, Munster, Germany
[6] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel
[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[8] Dong A Univ Coll Med, Dept Internal Med, Busan, South Korea
[9] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[10] Bayer AG, Pharmaceut Div, Wuppertal, Germany
[11] Univ Bologna, Inst Hematol L E A Seragnoli, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.7570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7570
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ohmachi, Ken
    Ando, Kiyoshi
    Ogura, Michinori
    Uchida, Toshiki
    Itoh, Kuniaki
    Kubota, Nobuko
    Ishizawa, Kenichi
    Yamamoto, Joji
    Watanabe, Takashi
    Uike, Naokuni
    Choi, Ilseung
    Terui, Yasuhito
    Usuki, Kensuke
    Nagai, Hirokazu
    Uoshima, Nobuhiko
    Tobinai, Kensei
    CANCER SCIENCE, 2010, 101 (09) : 2059 - 2064
  • [32] Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Duell, Johannes
    Maddocks, Kami J.
    Gonzalez-Barca, Eva
    Jurczak, Wojciech
    Liberati, Anna Marina
    de Vos, Sven
    Nagy, Zsolt
    Obr, Ales
    Gaidano, Gianluca
    Abrisqueta, Pau
    Andre, Marc
    Dreyling, Martin
    Menne, Tobias F.
    Dirnberger-Hertweck, Maren
    Weirather, Johannes
    Ambarkhane, Sumeet
    Salles, Gilles A.
    BLOOD, 2019, 134
  • [33] A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
    Ando, Kiyoshi
    Ogura, Michinori
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Kim, Won Seog
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
    Dreyling, M.
    Morschhauser, F.
    Bouabdallah, K.
    Bron, D.
    Cunningham, D.
    Assouline, S. E.
    Verhoef, G.
    Linton, K.
    Thieblemont, C.
    Vitolo, U.
    Hiemeyer, F.
    Giurescu, M.
    Garcia-Vargas, J.
    Gorbatchevsky, I.
    Liu, L.
    Koechert, K.
    Pena, C.
    Neves, M.
    Childs, B. H.
    Zinzani, P. L.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2169 - 2178
  • [35] Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
    Tobinai, K
    Igarashi, T
    Itoh, K
    Kobayashi, Y
    Taniwaki, M
    Ogura, A
    Kinoshita, T
    Hotta, T
    Aikawa, K
    Tsushita, K
    Hiraoka, A
    Matsuno, Y
    Nakamura, S
    Morio, S
    Ohashi, Y
    ANNALS OF ONCOLOGY, 2004, 15 (05) : 821 - 830
  • [36] Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6-year follow-up of CHRONOS-1
    Dreyling, M.
    Santoro, A.
    Mollica, L.
    Leppa, S.
    Follows, G.
    Lenz, G.
    Kim, W. S.
    Nagler, A.
    Panayiotidis, P.
    Ozcan, M.
    Kosinova, M.
    Provencio, M.
    Magagnoli, M.
    Bouabdallah, K.
    Diong, C. Phipps
    Munoz, J.
    Cao, A.
    Hiemeyer, F.
    Odongo, F.
    Garcia-Vargas, J.
    Childs, B.
    Zinzani, P. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 51 - 52
  • [37] Prolonged Lymphocytepenia after Bendamustine with or without Rituximab Treatment in Patients with Relapsed or Refractory Indolent B-Cell and Mantle Cell Lymphoma
    Saito, Hideaki
    Maruyama, Dai
    Maeshima, Akiko Miyagi
    Makita, Shin-ichi
    Kitahara, Hideaki
    Miyamoto, Ken-ichi
    Fukuhara, Suguru
    Munakata, Wataru
    Suzuki, Tatsuya
    Kobayashi, Yukio
    Taniguchi, Hirokazu
    Tobinai, Kensei
    BLOOD, 2014, 124 (21)
  • [38] A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma (vol 165, pg 768, 2014)
    Ogura, Michinori
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (04) : 629 - 629
  • [39] A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
    Tuscano, Joseph M.
    Maverakis, Emanual
    Groshen, Susan
    Tsao-Wei, Denice
    Luxardi, Guillaume
    Merleev, Alexander A.
    Beaven, Anne
    DiPersio, John F.
    Popplewell, Leslie
    Chen, Robert
    Kirschbaum, Mark
    Schroeder, Mark A.
    Newman, Edward M.
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7004 - 7013
  • [40] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study
    Bennani, N. Nora
    Nowakowski, Grzegorz
    Rimsza, Lisa M.
    Adjei, Alex A.
    Doyle, Laurence
    Ansell, Stephen M.
    BLOOD, 2019, 134
12345